Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.

Dempsey M, Mocarski M, Langer J, Hunt B

Journal of medical economics6 Sept 2018Cited by 4 (Europe PMC)

PMID30114954DOI10.1080/13696998.2018.1513406PepBankPUB-30114954

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01Computer modelNot a test of Liraglutide aloneIn silicoOther
In a modelled analysis of adults with type 2 diabetes on basal insulin, IDegLira increased discounted life expectancy by 0.02 years versus insulin glargine U100 plus insulin aspart.
In plain wordsIn a computer model of type 2 diabetes treatment, IDegLira gave a slightly longer life expectancy than glargine plus aspart insulin.
Peptide
Liraglutide
Outcome
IncreaseDiscounted life expectancy
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Insulin glargine U100 plus insulin aspart
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Discounted life expectancy gain
0.02 years
IDegLira
Source sentences
Summary
IDegLira was associated with increased discounted life expectancy by 0.02 years and increased discounted quality-adjusted life expectancy by 0.22 quality-adjusted life years compared with insulin glargine U100 plus insulin aspart.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira for treatment of patients with type 2 diabetes mellitus not meeting glycemic targets on basal insulin, vs insulin glargine U100 plus insulin aspart, in the US setting.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3011495401
02Computer modelNot a test of Liraglutide aloneIn silicoOther
In a modelled analysis of adults with type 2 diabetes on basal insulin, IDegLira increased discounted quality-adjusted life expectancy by 0.22 quality-adjusted life years versus insulin glargine U100 plus insulin aspart.
In plain wordsIn a computer model of type 2 diabetes treatment, IDegLira gave more years of good-quality life than glargine plus aspart insulin.
Peptide
Liraglutide
Outcome
IncreaseDiscounted quality-adjusted life expectancy
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Insulin glargine U100 plus insulin aspart
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Quality-adjusted life expectancy gain
0.22 QALY
IDegLira
Source sentences
Summary
increased discounted quality-adjusted life expectancy by 0.22 quality-adjusted life years compared with insulin glargine U100 plus insulin aspart.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira for treatment of patients with type 2 diabetes mellitus not meeting glycemic targets on basal insulin, vs insulin glargine U100 plus insulin aspart, in the US setting.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3011495402
03Computer modelNot a test of Liraglutide aloneIn silicoOther
In a modelled analysis of adults with type 2 diabetes on basal insulin, the mean cost per patient with IDegLira was $3,571 lower than with insulin glargine U100 plus insulin aspart.
In plain wordsIn a computer model of type 2 diabetes treatment, IDegLira cost less per case than glargine plus aspart insulin.
Peptide
Liraglutide
Outcome
DecreaseMean direct medical cost per patient
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Insulin glargine U100 plus insulin aspart
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
Evaluation of direct medical costs suggested that the mean cost per patient with IDegLira was $3,571 lower than with insulin glargine U100 plus insulin aspart.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira for treatment of patients with type 2 diabetes mellitus not meeting glycemic targets on basal insulin, vs insulin glargine U100 plus insulin aspart, in the US setting.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3011495403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.